CHANGE MY LOCATION
Business and Finance
Business News
Bush, allies seek to calm jittery investors- President Bush and the world's financial leaders staged repeated displays of unity Saturday to combat an unfolding credit crisis, hoping to calm investors whose panic has spread despite bold and accelerating government action.
- After consulting with Barack Obama, Democratic leaders are likely to call Congress back to work after the election in hopes of passing legislation that would include extended jobless benefits, money for food stamps and possibly a tax rebate, officials said Saturday.
- Hundreds of terrified Christian families have fled Mosul to escape extremist attacks that have increased despite months of U.S. and Iraqi military operations to secure the northern Iraqi city, political and religious officials said Saturday.
Rep. Lewis says McCain 'sowing seeds of hatred'- Rep. John Lewis, a Georgia Democrat and veteran of the civil rights movement, says the negative tone of the Republican presidential campaign reminds him of the hateful atmosphere that segregationist Gov. George Wallace fostered in Alabama in the 1960s.
- National forests and parks - long popular with Mexican marijuana-growing cartels - have become home to some of the most polluted pockets of wilderness in America because of the toxic chemicals needed to eke lucrative harvests from rocky mountainsides, federal officials said.
- For General Motors Corp. to acquire Chrysler LLC and all of its warts, GM would have to get desperately needed cash as part of the deal. Lots of it, according to industry analysts.
Lisa Marie Presley gives birth to twins- Lisa Marie Presley is a mom again. A publicist says the 40-year-old singer gave birth Tuesday to twin girls, whose names were not released. One baby weighed 5 pounds, 15 ounces and the other came in at 5 pounds and 2 ounces.
Kenya's elephants send text messages to rangers- The text message from the elephant flashed across Richard Lesowapir's screen: Kimani was heading for neighboring farms.
McCoy, No. 5 Longhorns upset No. 1 Sooners 45-35- The Texas Longhorns came into their annual showdown against the Oklahoma Sooners with a quarterback they could trust and a defense playing great under an aggressive new coordinator. Yet even after five solid wins, coach Mack Brown still wondered how good they were.
BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
BRISBANE, Calif.
(Map)
-
The company is evaluating BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in its DNA repair portfolio, as a monotherapy for patients whose ovarian cancer is linked to a hereditary genetic defect. Clinicians at Memorial Sloan-Kettering Cancer Center will enroll patients who have a mutation in their BRCA1 or BRCA2 genes.
"We believe BSI-201 holds great promise as a targeted therapy in this
difficult-to-treat type of ovarian cancer," said
Ovarian cancer strikes more than 21,000 women a year in
"We have identified a number of important types of cancer where PARP plays
a crucial role in tumor growth, and we believe that BRCA-negative ovarian
cancer represents another excellent target for BSI-201," said
The company is currently conducting a Phase 2 trial of BSI-201 in triple-
negative breast cancer and is collaborating with the New Approaches to Brain
Tumor Therapy (NABTT) consortium, a National Cancer Institute-funded research
group, to test BSI-201 in glioblastoma multiforme (GBM), the most common brain
cancer in adults. An additional trial in uterine cancer is expected to begin
enrollment in the coming weeks. The company also plans to present data from
its Phase 1 trials of BSI-201 in solid tumors at the American Society of
Clinical Oncology Annual Meeting that begins later this month in
About BiPar Sciences
BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials in breast, brain and ovarian cancer.
|
|
More Business_and_Finance Releases
(ERJ): Embraer-Empresa Brasileira De Aeronautica S.A. Market Announcement
(MGPI): Union Local Accepts Labor Agreement Reinstatement Offer at MGP Ingredients, Inc. Atchison, Kan., Plant
